Author

Pamela Zee

Observed name: P Zee

Institution: Bristol-Myers Squibb (United States)

Observed institution: Bristol-Myers Squibb (United States)

OpenAlex ID: A5018624929

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin

2014 · Julio Rosenstock, Lars Hansen, et al. · Diabetes Care · 290

PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)—Rationale and Design

2019 · Sarah O'Brien, Danshi Li, et al. · Thrombosis and Haemostasis · 63

Quantitative Extrapolation: An Approach to Validation of Adult Drug Efficacy in Pediatric Subjects

2013 · Tarek A. Leil, Pamela Zee, et al. · Therapeutic Innovation & Regulatory Science · 5

Duale Add-on-Therapie bei unter Metformin unzureichend kontrolliertem Typ 2 Diabetes: Randomisierte, doppelblinde Studie mit Saxagliptin plus Dapagliflozin vs. Saxagliptin oder Dapagliflozin allein

2015 · J Rosenstock, L Hansen, et al. · Diabetologie und Stoffwechsel

Works count: 4

Citation count: 358

H-index: 3

I10-index: 2